Survodutide (BI 456906)

Dual Glucagon/GLP-1 Receptor Agonist
For Laboratory Research Reference Only – Not for Human or Animal Use

Overview (in simple terms):

• What it is: Survodutide is a synthetic, long-acting peptide that activates both the glucagon receptor and the GLP‑1 receptor. This dual action can both increase energy burning and suppress appetite—a promising combo for weight management research Financial Times+14zealandpharma.com+14Taylor & Francis Online+14.

• Improvements on natural hormones: Unlike oxyntomodulin-based compounds, Survodutide is derived from glucagon but engineered for extended stability and once-weekly use Wikipedia.

Research Highlights:

• Weight loss & metabolic benefits: Meta-analysis of 18 trial arms (1,029 participants) showed significant reductions:

  • Weight: –8.33 kg average (95% CI: –10.80 to –5.86 kg)

  • BMI: –4.03 kg/m² average (95% CI: –4.86 to –3.20)

  • Waist circumference: –6.33 cm average (95% CI: –8.85 to –3.81 cm) PMC+1.

• Dose & duration matter: Greater effects were seen with >2 mg/week dosing and interventions longer than 16 weeks PMC.

• Age-related response: Participants under 50 years old responded more robustly than those older than 50ScienceDirect+6PMC+6Boehringer Ingelheim+6.

• Liver health & MASH improvement: In a mid-stage (Phase II) trial, Survodutide significantly improved liver histology in metabolic dysfunction-associated steatohepatitis (MASH), with ∼83% of patients showing symptom improvements compared to placebo Wikipedia+14Reuters+14Financial Times+14.

• Pharmacological and safety profile: Established as dose-dependent and tolerable in trials; aimed at reducing body weight while addressing both obesity and associated metabolic conditions

FDA-Style Disclaimer:

This product summary is intended solely for laboratory research reference. Survodutide is not a drug, supplement, cosmetic, or food, and has not been approved by the U.S. FDA for any clinical application. Not for human or animal consumption.